In the Webster’s investment dictionary, RVX is defined as a company that jerry-rigs it’s financings in an in-coherent manner.

The various piecemeal financings over the years are both fascinating and disturbing. I don’t know whether Don is a magician or has no clue how to run a company. Assuming this closes, you have got to love a loan. Why has no major pharma other than Hepa (not a household name in North America) every stepped-up. You can assume with the terms provided in the various financings, one would have stepped forward. On the other hand, why would Third Eye put up some much capital assuming the loan closes (a significant investment if you look at their other financings) with such "apparent" risk attached? It looks like to me this is either a repayment and exercise of warrants at a large profit, or a bad loan. Not the usual risk profile funders take (they like little risk and a lot of profit), so you have to think the think the loan is de-risked is their mind.

So we come back to the final comments of the PR. “This is a significant financing step for Resverlogix as we advance toward the completion of the critical Phase 3 BETonMACE trial which is expected to unlock the true financial potential of the Company’s epigenetic technology”.

So in hopefully less than 8 months, we will be proven either visionaries or idiots or knowing RVX, somehow a positive result will end up leaving us still wanting and big pharma will want something else before they move.